Ribometrix
Business Services · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
6 Davis Dr Ste 159, Durham, North Caroli...Phone Number
(919) 404-7426Website
www.ribometrix.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Ribometrix
Ribometrix is pioneering a new approach in drug discovery by developing small molecule therapeutics that target cellular RNAs to correct the production of disease-causing proteins. The company combines traditional drug discovery practices with innovative RNA-targeting technologies to address a wide range of diseases. Ribometrix collaborates with strategic partners to advance its mission of RNA modulation through small molecules. Headquartered in North Carolina's Research Triangle Park, Ribometrix is at the forefront of a potentially transformative field in medicine.Explore more
Ribometrix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ribometrix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Ribometrix, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Ribometrix had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Ribometrix has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Ribometrix recently announced quarterly report
Check out if Ribometrix is spiking on competitors!
Funding: Get notified immidiatlly once Ribometrix has new funding data
Product Launch: Get notified when Ribometrix launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Ribometrix
Recommended Actions
Find VP level buyers at Ribometrix
Find 2 more new buyers
Compare Similar Companies to Ribometrix
Compare insights from companies similar to Ribometrix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ribometrix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ribometrix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ribometrix.
Ribometrix financials insights
Gather financial insights about Ribometrix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Angel/Seed
$7.5M
2018
Series A
$30M
2019
Other Financing Round
$7.8M
Ribometrix Tech Stack
A closer look at the technologies used by Ribometrix
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Event
Events
Left Company
Executive Move
Ribometrix News & Media
Ribometrix Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024
DURHAM, N.C.--(BUSINESS WIRE)--Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, presented the latest data from its eIF4E program at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain, September 13-17. The poster presentation reviews in vitro and in vivo studies of a small molecule eIF4E inhibitor, RBX-6610, as a potential treatment for KRASG12C mutant non-small cell lung cancer (NSCLC). Acquired resistRibometrix To Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024
DURHAM, N.C.--(BUSINESS WIRE)--Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, today announced the latest data from its eIF4E program will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain, September 13-17. A poster presentation will review in vitro and in vivo studies of a small molecule eIF4E inhibitor, RBX-6610, as a potential treatment for non-small cell lung cancer (NSCLC), speciRibometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024
DURHAM, N.C.--(BUSINESS WIRE)--Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, today shared the full data from two posters highlighting advancements across two distinct modalities presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, held April 5-10 in San Diego, CA. The posters include the company’s first public disclosure of data validating its RNA-targeting platform for designing small molecules to bind dirRibometrix to Present New Preclinical Data From RNA-Modulating Small Molecule Programs Targeting eIF4E and c-MYC at the 2024 AACR Annual Meeting
DURHAM, N.C.--(BUSINESS WIRE)--Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, today announced it will present two posters with preclinical data highlighting advancements across two distinct modalities at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The posters will show in vivo anti-tumor efficacy of Ribometrix’s lead candidate targeting the RNA-binding protein eIF4E in combination with standard-of-care across mu
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ribometrix
Sign Up For FreeTo access detailed company insights
Ribometrix is pioneering a new approach in drug discovery by developing small molecule therapeutics that target cellular RNAs to correct the production of disease-causing proteins. The company combines traditional drug discovery practices with innovative RNA-targeting technologies to address a wide range of diseases. Ribometrix collaborates with st... Read More
